LINC01270 Regulates the NF-κB-Mediated Pro-Inflammatory Response via the miR-326/LDOC1 Axis in THP-1 Cells

Area of Science:

• Molecular Biology
• Immunology
• Genetics

Background:

• Long noncoding RNAs (lncRNAs) are increasingly implicated in various diseases.
• The specific role of LINC01270 in inflammatory processes remains largely unexplored.
• Understanding lncRNA functions is crucial for developing novel therapeutic strategies.

Purpose of the Study:

• To investigate the role of LINC01270 in regulating inflammatory responses in human monocytic leukemia (THP-1) cells.
• To elucidate the molecular mechanisms underlying LINC01270's influence on inflammation.
• To identify potential therapeutic targets for inflammatory diseases.

Main Methods:

• Lipopolysaccharide (LPS) stimulation of THP-1 cells to induce inflammation.
• siRNA-mediated knockdown of LINC01270 to assess its functional impact.
• Analysis of NF-κB activity and cytokine production (IL-6, IL-8, MCP-1).
• Investigating the interaction with leucine zipper downregulated in cancer 1 (LDOC1) and micro-RNA 326 (miR-326).
• Luciferase reporter assays in HEK293 cells to confirm regulatory interactions.

Main Results:

• LPS treatment upregulated LINC01270 expression in THP-1 cells.
• LINC01270 knockdown enhanced NF-κB activation and pro-inflammatory cytokine production.
• Knockdown of LINC01270 led to decreased expression of LDOC1, a known NF-κB suppressor.
• The miR-326/LDOC1 axis was identified as a key mediator in LINC01270's regulatory function.
• Perturbation of the LINC01270/miR-326/LDOC1 interaction modulated inflammatory responses.

Conclusions:

• LINC01270 plays a significant role in negatively regulating inflammatory responses to LPS in THP-1 cells.
• The miR-326/LDOC1 axis is a critical pathway through which LINC01270 modulates NF-κB activation.
• LINC01270 represents a potential therapeutic target for managing inflammatory conditions.